Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.Chem Commun (Camb). 2020 Aug 07; 56(61):8683-8686.CC
Abstract
Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.
Links
MeSH
Angiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsFemaleHumansMiceMice, Inbred C57BLPandemicsPeptidyl-Dipeptidase APneumonia, ViralProtein BindingRecombinant Fusion ProteinsSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SubunitViral Vaccines
Pub Type(s)
Journal Article
Language
eng
PubMed ID
32613971
Citation
Qi, Xiaoxiao, et al. "Construction and Immunogenic Studies of a mFc Fusion Receptor Binding Domain (RBD) of Spike Protein as a Subunit Vaccine Against SARS-CoV-2 Infection." Chemical Communications (Cambridge, England), vol. 56, no. 61, 2020, pp. 8683-8686.
Qi X, Ke B, Feng Q, et al. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chem Commun (Camb). 2020;56(61):8683-8686.
Qi, X., Ke, B., Feng, Q., Yang, D., Lian, Q., Li, Z., Lu, L., Ke, C., Liu, Z., & Liao, G. (2020). Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chemical Communications (Cambridge, England), 56(61), 8683-8686. https://doi.org/10.1039/d0cc03263h
Qi X, et al. Construction and Immunogenic Studies of a mFc Fusion Receptor Binding Domain (RBD) of Spike Protein as a Subunit Vaccine Against SARS-CoV-2 Infection. Chem Commun (Camb). 2020 Aug 7;56(61):8683-8686. PubMed PMID: 32613971.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
AU - Qi,Xiaoxiao,
AU - Ke,Bixia,
AU - Feng,Qian,
AU - Yang,Deying,
AU - Lian,Qinghai,
AU - Li,Zibo,
AU - Lu,Linlin,
AU - Ke,Changwen,
AU - Liu,Zhongqiu,
AU - Liao,Guochao,
Y1 - 2020/07/02/
PY - 2020/7/3/pubmed
PY - 2020/8/11/medline
PY - 2020/7/3/entrez
SP - 8683
EP - 8686
JF - Chemical communications (Cambridge, England)
JO - Chem Commun (Camb)
VL - 56
IS - 61
N2 - Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.
SN - 1364-548X
UR - https://www.unboundmedicine.com/medline/citation/32613971/Construction_and_immunogenic_studies_of_a_mFc_fusion_receptor_binding_domain__RBD__of_spike_protein_as_a_subunit_vaccine_against_SARS_CoV_2_infection_
DB - PRIME
DP - Unbound Medicine
ER -